Stockreport

Vincerx Pharma Presents Data On PTEFb/CDK9 Inhibitor VIP152 In DLBCL And CLL At The 63rd American Society Of Hematology Annual Meeting [TheStreet.com]

Vincerx Pharma, Inc.  (VINC) 
PDF VIP152 has increased selectivity and potency compared to other CDK9 inhibitors in development, consistent across DLBCL and CLL models of disease Vincerx hosting KOL web [Read more]